Payment overview · 2025
General Payments
$432.87
23 reported records · 11 companies
Healthcare provider profile · identity verified
John Brian Fowler, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SPARTANBURG, SC · NPI 1538131933
Verified facts
What the public records show
CMS Open Payments records show John Brian Fowler, MD received $432.87 in general payments during 2025 across 23 reported records.
Dexcom, Inc. accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $92.17 | 21.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $68.28 | 15.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.88 | 13.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $52.08 | 12.0% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $46.46 | 10.7% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $23.61 | 5.5% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $20.78 | 4.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.93 | 4.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.83 | 4.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.47 | 4.3% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $14.38 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $432.87 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $92.17 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $57.88 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $57.88 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.88 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $46.46 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $38.44 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $33.13 | 2 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 101 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 139 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
46 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
101 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lorazepam | Lorazepam | 649 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 538 | 160 |
| Amlodipine Besylate | Amlodipine Besylate | 526 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 490 | 133 |
| Alprazolam | Alprazolam | 489 | 66 |
| Lisinopril | Lisinopril | 443 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 410 | 123 |
| Gabapentin | Gabapentin | 392 | 85 |
| Losartan Potassium | Losartan Potassium | 385 | 113 |
| Omeprazole | Omeprazole | 380 | 111 |
| Prednisone | Prednisone | 344 | 182 |
| Tramadol Hcl | Tramadol Hcl | 324 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 313 | 93 |
| Glipizide | Glipizide | 294 | 73 |
| Furosemide | Furosemide | 283 | 95 |
| Clonazepam | Clonazepam | 277 | 37 |
| Azithromycin | Azithromycin | 263 | 164 |
| Zolpidem Tartrate | Zolpidem Tartrate | 241 | 34 |
| Meloxicam | Meloxicam | 230 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 219 | 64 |
| Escitalopram Oxalate | Escitalopram Oxalate | 208 | 60 |
| Metformin Hcl | Metformin Hcl | 201 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 197 | 57 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 181 | 55 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 180 | 21 |
| Diazepam | Diazepam | 180 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 174 | 52 |
| Potassium Chloride | Potassium Chloride | 174 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 158 | 34 |
| Montelukast Sodium | Montelukast Sodium | 158 | 46 |
| Simvastatin | Simvastatin | 157 | 41 |
| Carvedilol | Carvedilol | 155 | 47 |
| Sertraline Hcl | Sertraline Hcl | 142 | 35 |
| Ozempic | Semaglutide | 139 | 24 |
| Trazodone Hcl | Trazodone Hcl | 135 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 133 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 132 | 30 |
| Levofloxacin | Levofloxacin | 124 | 86 |
| Hydrochlorothiazide | Hydrochlorothiazide | 123 | 35 |
| Allopurinol | Allopurinol | 120 | 32 |
| Ibuprofen | Ibuprofen | 119 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 37 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 111 | 70 |
| Estradiol | Estradiol | 106 | 31 |
| Eliquis | Apixaban | 101 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 84 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 84 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 80 | 68 |
| Ondansetron Odt | Ondansetron | 80 | 30 |
| Promethazine Hcl | Promethazine Hcl | 77 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 17 |
| Pregabalin | Pregabalin | 73 | 18 |
| Testosterone Cypionate | Testosterone Cypionate | 73 | 11 |
| Ezetimibe | Ezetimibe | 71 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 70 | 24 |
| Donepezil Hcl | Donepezil Hcl | 69 | 14 |
| Glimepiride | Glimepiride | 66 | 20 |
| Celecoxib | Celecoxib | 65 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 13 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 62 | 28 |
| Mounjaro | Tirzepatide | 62 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 13 |
| Amoxicillin | Amoxicillin | 61 | 38 |
| Bupropion Xl | Bupropion Hcl | 58 | 12 |
| Carisoprodol | Carisoprodol | 58 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 19 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 55 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 20 |
| Atenolol | Atenolol | 54 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 29 |
| Warfarin Sodium | Warfarin Sodium | 50 | 13 |
| Temazepam | Temazepam | 49 | 12 |
| Spironolactone | Spironolactone | 48 | 19 |
| Fluconazole | Fluconazole | 47 | 33 |
| Symbicort | Budesonide/Formoterol Fumarate | 46 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 44 | 12 |
| Nystatin | Nystatin | 43 | 21 |
| Valacyclovir | Valacyclovir Hcl | 43 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 42 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 12 |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 39 | 11 |
| Famotidine | Famotidine | 38 | 13 |
| Divalproex Sodium | Divalproex Sodium | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 37 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Mirtazapine | Mirtazapine | 36 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Fenofibrate | Fenofibrate | 35 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Acyclovir | Acyclovir | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 30 | 26 |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 16 |
| Baclofen | Baclofen | 23 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 14 |
| Olanzapine | Olanzapine | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Humira(Cf) Pen | Adalimumab | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Testosterone | Testosterone | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $432.87 · 23 records | Dexcom, Inc. | BREZTRI, CT THROMBECTOMY SYSTEM KIT, Dexcom G6 Transmitter, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ELIQUIS, FLOWTRIEVER CATHETER, S, JARDIANCE, KRYSTEXXA, NEFFY, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error